Evidence map›Paper›PMID 39283712›Full record

ArticleJournal of the National Cancer Institute2024

Lung cancer screening with low-dose computed tomography-where do we go from here?

Ashley Elizabeth Prosper, Yannan Lin, Denise R Aberle

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of the National Cancer Institute, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Ashley Elizabeth ProsperMedical and Imaging Informatics, Department of Radiological Sciences, David Geffen School of Medicine University of California Los Angeles (UCLA), Los Angeles, CA, USA.ORCID 0000-0001-8615-5246
Yannan LinMedical and Imaging Informatics, Department of Radiological Sciences, David Geffen School of Medicine University of California Los Angeles (UCLA), Los Angeles, CA, USA.ORCID 0000-0003-3514-6475
Denise R AberleMedical and Imaging Informatics, Department of Radiological Sciences, David Geffen School of Medicine University of California Los Angeles (UCLA), Los Angeles, CA, USA.ORCID 0000-0002-8858-3401

Funding

The Boston University - UCLA Lung Cancer Biomarker Characterization CenterU2CCA271898 · NCI · BOSTON UNIVERSITY MEDICAL CAMPUS · PI Jennifer Ellen Beane, Steven M. Dubinett · 2022 to 2026
$5.5M
Molecular and Imaging Biomarkers for Early Lung Cancer Detection in the Setting of Indeterminate Pulmonary NodulesR01CA210360 · NCI · BOSTON UNIVERSITY MEDICAL CAMPUS · PI ABERLE, DENISE R., LENBURG, MARC ELLIOTT · 2016 to 2021
$3.1M
Individually-tailored clinical decision support for management of indeterminate pulmonary nodulesR01CA226079 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ABERLE, DENISE R., BUI, ALEX · 2019 to 2023
$2.3M
NCI NIH HHS R01 CA210360NCI NIH HHS R01 CA226079NCI NIH HHS U2C CA271898NIHNIH HHS U2C CA271898
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID39283712
PMCPMC11630503

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.